Table 1 Comparison of parameters at baseline and after eight weeks of placebo and pravastatin treatment, respectively.
| Baseline n = 29 | Placebo 8 weeks n = 29 | Pravastatin 8 weeks n = 29 | p Value pravastatin v baseline | p Value pravastatin v placebo | |
|---|---|---|---|---|---|
| HIV surrogate markers | |||||
| CD4 cell count (103 cells/ml) | 484 (328–633) | 472 (320–646) | 464 (354–650) | 0.60 | 0.42 |
| HIV‐1 RNA (copies/ml) | 8 (0–37) | 0 (0–22) | 0 (0–18) | 0.57 | 0.33 |
| Clinical parameters | |||||
| Body mass index (kg/m2) | 22.9 (21.4–25.1) | 23.1 (21.3–25.1) | 22.6(21.2–25.4) | 0.53 | 0.93 |
| Systolic blood pressure (mm Hg) | 120 (114–128) | 118 (114–129) | 119 (113–127) | 0.33 | 0.99 |
| Diastolic blood pressure (mm Hg) | 77 (71–83) | 78 (73–83) | 76 (71–84) | 0.41 | 0.95 |
| Heart rate (bpm) | 76 (71–81) | 75 (70–82) | 75 (71–80) | 0.85 | 0.47 |
| Laboratory parameters | |||||
| Total cholesterol (mmol/l) | 6.4 (6.0–7.4) | 6.4 (5.3–7.2) | 5.5 (4.8–6.3) | <0.0001 | 0.001 |
| HDL cholesterol (mmol/l) | 1.2 (1.1–1.6) | 1.2 (1.0–1.6) | 1.3 (1.1–1.4) | 0.90 | 0.38 |
| LDL cholesterol (mmol/l) | 3.7 (2.8–4.2) | 3.9 (2.7–4.4) | 3.0 (2.4–3.7) | 0.001 | 0.01 |
| Triglycerides (mmol/l) | 3.0 (2.1–4.0) | 2.7 (2.1–3.8) | 2.3 (1.6–2.9) | 0.05 | 0.04 |
| Oxidised LDL (IU) | 53 (45–66) | 55 (43–70) | 47 (38–57) | 0.0003 | 0.007 |
| hs CRP (mg/l) | 2.2 (0.7–4.5) | 2.1 (0.8–5.1) | 2.1 (1.0–4.8) | 0.50 | 0.29 |
| Endothelial function | |||||
| % FMD | 2.0 (1.5–2.6) | 2.5 (1.8–3.2) | 3.2 (1.9–4.1) | 0.003 | 0.03 |
| % GTN induced vasodilatation | 11.3 (10.0–14.4) | 11.3 (9.6–16.3) | 10.8 (7.0–15.7) | 0.16 | 0.85 |
| Vessel diameter (mm) | 4.4 (4.1–4.8) | 4.3 (3.8–4.6) | 4.3 (3.9–4.8) | 0.26 | 0.65 |
Data are presented as medians and interquartile range unless otherwise stated
GTN, glyceryl trinitrate; HDL, high density lipoprotein; hs CRP, high sensitivity C reactive protein; LDL, low density lipoprotein.